Publicaciones en colaboración con investigadores/as de Instituto Oftalmologico de Alicante (11)

2018

  1. Efficacy and safety of an aflibercept treat-and-extend regimen in treatment-naïve patients with macular oedema secondary to Central Retinal Vein Occlusion (CRVO): A Prospective 12-Month, Single-Arm, Multicentre Trial

    Journal of Ophthalmology, Vol. 2018

2015

  1. Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration

    Journal of Ophthalmology, Vol. 2015

2014

  1. A Delphi study to detect deficiencies and propose actions in real life treatment of neovascular age-related macular degeneration

    Journal of Ophthalmology, Vol. 2014

2012

  1. Three versus one intravitreal bevacizumab injections as initial protocol to treat myopic choroidal neovascularization

    Acta Ophthalmologica

2010

  1. Photodynamic therapy for chronic central serous chorioretinopathy

    Acta Ophthalmologica, Vol. 88, Núm. 3, pp. 371-376

  2. Twelve-month outcome after one intravitreal injection of bevacizumab to treat myopic choroidal neovascularization

    Retina, Vol. 30, Núm. 10, pp. 1609-1615

2009

  1. A 1-year retrospective review of ranibizumab for naïve nonsubfoveal choroidal neovascularization secondary to age-related macular degeneration

    Retina, Vol. 29, Núm. 10, pp. 1444-1449

  2. Efficacy of intravitreal bevacizumab to treat retinal angiomatous proliferation stage II and III

    European Journal of Ophthalmology, Vol. 19, Núm. 3, pp. 448-451

  3. Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome

    British Journal of Ophthalmology, Vol. 93, Núm. 4, pp. 448-451

  4. Intravitreous bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes: Short-term results

    Eye, Vol. 23, Núm. 2, pp. 334-338

  5. Photodynamic therapy may worsen the prognosis of highly myopic choroidal neovascularisation treated by intravitreal bevacizumab

    British Journal of Ophthalmology